Related Experiment Video
Updated: Feb 26, 2026
08:21
Functional Assessment of the Donor Heart During Ex Situ Perfusion: Insights from Pressure-Volume Loops and Surface Echocardiography
Published on: October 11, 2022
2.7K
Impact of Compound Hypertonic Saline Solution on Decompensated Heart Failure
Yanfang Wan1, Lei Li1, Heping Niu1
1Department of Cardiology, Cangzhou Central Hospital, Hebei Medical University.
International Heart Journal
|July 14, 2017
Summary
Compound hypertonic saline solution (C-HSS) with furosemide significantly reduced hospitalization time, readmission rates, and mortality in heart failure patients. This treatment offers a promising approach for managing decompensated heart failure (NYHA class III).
Area of Science:
- Cardiology
- Nephrology
- Internal Medicine
Background:
- Heart failure (HF) management, particularly for New York Heart Association (NYHA) class III patients, presents significant challenges in reducing hospitalizations and mortality.
- Optimizing diuretic therapy and fluid management is crucial for improving outcomes in decompensated heart failure.
Purpose of the Study:
- To investigate the efficacy of compound hypertonic saline solution (C-HSS) combined with high-dose furosemide in managing NYHA class III heart failure.
- To evaluate the impact of C-HSS on hospitalization duration, readmission frequency, and patient mortality.
Main Methods:
- A randomized open-label study involving 264 NYHA class III heart failure patients with ejection fraction < 40%.
- Group 1 received furosemide (100 mg IV infusion) plus C-HSS (100 mL) twice daily with severe water restriction (500 mL/day).
- Group 2 received furosemide (100 mg IV bolus) twice daily with water restriction (500 mL/day), without C-HSS. Both groups maintained normal sodium intake (120 mmol/day).
Main Results:
- The C-HSS group exhibited increased urination, significantly reduced hospitalization time (4 ± 2 vs. 7 ± 2 days, P < 0.01), and lower hospitalization costs (2210 vs. 3506 RMB, P < 0.01).
- Over a 36 ± 12 month follow-up, the C-HSS group showed a significantly longer average readmission time (31.84 ± 7.58 vs. 15.60 ± 6.25 months, P < 0.01).
- Mortality rates were significantly lower in the C-HSS group (16.5% vs. 31.9%, P < 0.01).
Conclusions:
- Periodical administration of C-HSS, alongside strict water restriction and a normal sodium diet, is effective in reducing hospitalization duration in NYHA class III heart failure.
- This therapeutic strategy significantly decreases readmission rates and lowers mortality in patients with decompensated heart failure.
- C-HSS represents a valuable adjunct therapy for improving long-term outcomes in heart failure management.
Related Concept Videos
01:22Heart Failure Drugs: Diuretics
1.1K
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
1.1K
01:30Heart Failure V: Medical Management
419
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
419
01:29Heart Failure II: Pathophysiology
1.1K
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.1K
01:22Heart Failure VI: Adjunct Therapies
466
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
466
01:26Heart Failure Drugs: Inotropic Agents
1.7K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.7K
01:17Pathophysiology of Heart Failure
4.1K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
4.1K